Poland· PL-100353050

Praluent

A alirocumab product containing alirocumabum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 15 of our 19 countries.

ATC C10AX14

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPraluentATCC10AX14REGISTER NO.PL-100353050PACKS LISTED10CHECKEDSeptember 27, 2026

Where it is registered

Alirocumab is registered in 15 of 19 countries.

Countries holding a registration under ATC C10AX14 (alirocumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Alirocumab · ATC C10AX14

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of alirocumab costs, country by country.

Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Alirocumab · price per daily dose (5.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$16.93
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Alirocumabum
Manufacturer
Sanofi Winthrop Industrie
Country
Poland (PL)
ATC code
C10AX14
ATC class
Alirocumab
Defined daily dose
5.4 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 10

  • gtin
    05909991236540
  • gtin
    05909991236557
  • gtin
    05909991236564
  • gtin
    05909991236571
  • gtin
    05909991236588
  • gtin
    05909991236595
  • gtin
    05909991441104
  • gtin
    05909991441111
  • gtin
    05909991441128
  • gtin
    05909991561482

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/61537904-e8bb-4675-baec-6b0b87b3b9d8
GET /v1/drugs/61537904-e8bb-4675-baec-6b0b87b3b9d8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "75 mg",
  "packaging": "05909991236540 ¦ Rp ¦ EU/1/15/1031/001 ¦ 110682\n1 wstrzykiwacz 1 ml\n05909991236557 ¦ Rp ¦ EU/1/15/1031/002 ¦ 110683\n2 wstrzykiwacze 1 ml\n05909991236564 ¦ Rp ¦ EU/1/15/1031/003 ¦ 110684\n6 wstrzykiwaczy 1 ml\n05909991236571 ¦ Rp ¦ EU/1/15/1031/004 ¦ 110685\n1 amp.-strzyk. 1 ml\n05909991236588 ¦ Rp ¦ EU/1/15/1031/005 ¦ 110686\n2 amp.-strzyk. 1 ml\n05909991236595 ¦ Rp ¦ EU/1/15/1031/006 ¦ 110687\n6 amp.-strzyk. 1 ml\n05909991441104 ¦ Rp ¦ EU/1/15/1031/013 ¦ 138153\n1 wstrzykiwacz 1 ml\n05909991441111 ¦ Rp ¦ EU/1/15/1031/014 ¦ 138154\n2 wstrzykiwacze 1 ml\n05909991441128 ¦ Rp ¦ EU/1/15/1031/015 ¦ 138155\n3 wstrzykiwaczy 1 ml\n05909991561482 ¦ Rp ¦ EU/1/15/1031/023 ¦ 159475\n3 wstrzyk. 1 ml (75 mg/ml)",
  "substance": "Alirocumabum 75 mg",
  "common_name": "Alirocumabum",
  "pl_product_id": "100353050",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about alirocumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.